Solangi K B, Lutton J D, Svogun J A, Ibraham N G, Goodman A I, Levere R D
Res Commun Chem Pathol Pharmacol. 1984 Jul;45(1):19-35.
We studied the effect of cimetidine on liver and kidney heme metabolism and on the activity of the cytochrome P-450 drug metabolizing enzyme system. Results show that the induction of a heme biosynthetic enzyme and the activities of two drug metabolizing enzymes are impaired when cimetidine is given in combination with phenobarbital (PB). When rats were given four 33 mg doses of cimetidine IP per day for 2 days and sacrificed, we found no significant effect on kidney or liver delta-aminolevulinic acid (ALA) synthase activity. Heme oxygenase and cytochrome P-450 levels were also unchanged in these tissues. In contrast, when we measured activities of certain liver drug metabolizing enzymes, it was found that cimetidine significantly inhibited aniline hydroxylase and aminopyrine-N-demethylase by 43% and 65%, respectively. The observed changes in the activities of these drug metabolizing enzymes led us to study cimetidine in combination with other drugs. When the porphyric inducing agent allylisoprophyacetamide (AIA) was administered alone, we found a 326% increase in hepatic ALA synthase activity at 16 hours. Cimetidine given together with AIA increases hepatic ALA synthase 291 and 300% at 16 and 20 hour intervals respectively. Cytochrome P-450 levels in AIA treated rats with or without cimetidine were decreased to 52-65% of control values without a significant change in heme oxygenase levels. When PB was given alone, we found an increase in hepatic ALA synthase activity by 223 and 400% at 16 and 20 hour intervals, respectively. Cimetidine in combination with PB at the same time intervals showed a slightly diminished increase of hepatic ALA synthase activity by 146 and 238%, respectively. When PB was given alone, hepatic cytochrome P-450 was increased 96% at 16 hours, whereas when combined with cimetidine a similar increase of hepatic cytochrome P-450 was observed. In conclusion cimetidine does not significantly alter the action of the porphyric agents PB and ALA on cytochrome P-450; however, combined administration of PB plus cimetidine does impair the induction of ALA synthase. Additionally, cimetidine markedly decreased the drug metabolizing enzymes aniline hydroxylase and aminopyrine-N-demethylase in vivo, and subsequently may interfere with the endogenous metabolism of other drugs.
我们研究了西咪替丁对肝脏和肾脏血红素代谢以及细胞色素P - 450药物代谢酶系统活性的影响。结果表明,当西咪替丁与苯巴比妥(PB)联合使用时,一种血红素生物合成酶的诱导以及两种药物代谢酶的活性会受到损害。当给大鼠每天腹腔注射4次33毫克西咪替丁,持续2天然后处死时,我们发现对肾脏或肝脏的δ-氨基乙酰丙酸(ALA)合酶活性没有显著影响。这些组织中的血红素加氧酶和细胞色素P - 450水平也没有变化。相比之下,当我们测量某些肝脏药物代谢酶的活性时,发现西咪替丁分别显著抑制苯胺羟化酶和氨基比林 - N - 脱甲基酶43%和65%。这些药物代谢酶活性的观察变化促使我们研究西咪替丁与其他药物的联合使用情况。当单独给予卟啉诱导剂烯丙基异丙基乙酰胺(AIA)时,我们发现在16小时时肝脏ALA合酶活性增加了326%。与AIA一起给予西咪替丁,在16小时和20小时间隔时分别使肝脏ALA合酶增加291%和300%。在有或没有西咪替丁的情况下,AIA处理的大鼠中的细胞色素P - 450水平降至对照值的52 - 65%,而血红素加氧酶水平没有显著变化。当单独给予PB时,我们发现在16小时和20小时间隔时肝脏ALA合酶活性分别增加223%和400%。在相同时间间隔下,西咪替丁与PB联合使用时,肝脏ALA合酶活性的增加略有减少,分别为146%和238%。当单独给予PB时,肝脏细胞色素P - 450在16小时时增加了96%,而当与西咪替丁联合使用时,观察到肝脏细胞色素P - 450有类似的增加。总之,西咪替丁不会显著改变卟啉剂PB和ALA对细胞色素P - 450的作用;然而,PB加西咪替丁的联合给药确实会损害ALA合酶的诱导。此外,西咪替丁在体内显著降低了药物代谢酶苯胺羟化酶和氨基比林 - N - 脱甲基酶,随后可能会干扰其他药物的内源性代谢。